Weight management

Semaglutide: the research history.

Semaglutide’s research history includes different doses, formulations and clinical settings. The weight-management question should retain the trial’s population and administered regimen.

5,187records matching the ingredient search

1connected formulations

6displayed publication records

How the research connects to the formula

STEP 1 tested once-weekly subcutaneous semaglutide 2.4 mg for sixty-eight weeks in adults without diabetes, alongside lifestyle intervention. Its reported mean weight change is a result from that defined comparison with placebo.

The amount in a vial and the weekly administered quantity are different fields. A purchasing period is also different from the trial follow-up period. Keeping these distinctions visible helps connect the evidence to the current product without turning a trial average into an individual forecast.

Current HealthRX.com formulation map
Product	Listed formulation	Connected ingredient research
Semaglutide	5mg/vial	Semaglutide

Publication history

When the ingredient appeared in the literature

The chart counts records mentioning the search terms in their title or abstract. It includes research beyond weight management. Use the period controls to inspect the count.

2026: 1,545 indexed publications. 2026 includes publications dated through October 5. The earlier bars cover longer periods than the annual bars.

View the chart as a data table

Period	Publications
1900-1959	0
1960-1969	0
1970-1979	0
1980-1989	0
1990-1999	0
2000-2009	0
2010-2014	4
2015-2019	292
2020	132
2021	200
2022	282
2023	426
2024	871
2025	1435
2026	1545

Search query and data source

Source: Europe PMC’s PubMed-indexed records. Retrieved October 5, 2026. The index’s firstPublicationDate field supplies the dates and chart periods; it can normalize a month-only record to the first day of the month. Dates through October 5 are included. Counts can change as the index adds or corrects records.

TITLE_ABS:(semaglutide) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]

Open this literature search · Download the data

Dated publications

Read individual records in context

The timeline combines selected references with a sample from the ingredient search. Dates use the index’s firstPublicationDate field; the PubMed record may distinguish an earlier online date from the print date. Written study notes appear alongside the records that have them. Other entries show the indexed bibliography and link to the paper.

Research Support, Non-U.S. Gov't · Multicenter Study · Randomized Controlled Trial · Journal Article

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. The New England journal of medicine. PMID 33567185.

Study design: Randomized controlled trial, 1,961 adults
What was tested: Once-weekly subcutaneous semaglutide 2.4 mg versus placebo, with lifestyle intervention, over 68 weeks.
What was reported: Mean body-weight change was -14.9% with semaglutide and -2.4% with placebo.
How it connects to the catalog: The endpoint belongs to this trial population, regimen and follow-up period. It should not be transferred to a different dose, oral formulation or fixed-duration purchasing plan.

Read the PubMed record · Publisher record

Study comparison

Publication	Design and regimen	Reported finding	Interpretation
2021-02-10: Once-Weekly Semaglutide in Adults with Overweight or Obesity.	Randomized controlled trial, 1,961 adults. Once-weekly subcutaneous semaglutide 2.4 mg versus placebo, with lifestyle intervention, over 68 weeks.	Mean body-weight change was -14.9% with semaglutide and -2.4% with placebo.	The endpoint belongs to this trial population, regimen and follow-up period. It should not be transferred to a different dose, oral formulation or fixed-duration purchasing plan.

Questions that shape the comparison

Was the studied formulation injectable or oral? Which population, escalation schedule and follow-up period produced the reported outcome?

Source records

Once-Weekly Semaglutide in Adults with Overweight or Obesity.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group.The New England journal of medicine. 2021-02-10. PMID 33567185. Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, Journal Article.

Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial.Lingvay I, Kushner RF, Kaul U, Kokkinos A, Lincoff AM, Pall D, Pietilä M, Plutzky J, Stensen S, Bogdański P, Brown P, Cercato C, Dagdelen S, Deanfield J, Hovingh GK, Kahn SE, Ryan DH.Diabetes care. 2026-09-24. PMID 42782193. Journal Article.

Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?Zhou XD, Alkhouri N, Schattenberg JM, Muthiah MD, Tacke F, Zheng MH.eGastroenterology. 2026-09-25. PMID 42825265. discussion, Journal Article.

Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.Wang S, Dong B, Shen Z.Diabetes therapy : research, treatment and education of diabetes and related disorders. 2026-09-28. PMID 42803912. Journal Article.

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.Tuttle KR, Bjornstad P, Smith C, Pruijm M, McCown PJ, Hodgin JB, Cherney DZI, Belmar N, Chacko MM, Das V, Gunnarsson TP, Idorn T, Schytz PA, Zaratiegui A, Kretzler M.Nature medicine. 2026-10-01. PMID 42823485. Journal Article.

The effect of submaximal doses of semaglutide on the expression of micro-RNA in patients with obesity: a pilot study.Jurica J, Miertova Z, Pec MJ, Focko B, Miert A, Tudik P, Nagy N, Sagova I, Pecova M, Bolek T, Galajda P, Sarlinova M, Dvorska D, Brany D, Baranova I, Kapinova A, Dankova Z, Halasova E, Mokan M, Samoš M.Obesity facts. 2026-10-01. PMID 42821500. Journal Article.

Research data assembled by HealthRX.com from the displayed source records, October 5, 2026. The atlas contains a dated literature search and selected studies; it is not an exhaustive systematic review.